Dolutegravir bests darunavir in first-line HIV setting
This article was originally published in Scrip
Initial results from an ongoing multinational, open label trial within a suite of studies for ViiV Healthcare's dolutegravir have bolstered evidence of efficacy for the integrase strand transfer inhibitor in the first-line treatment of HIV.
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.